title: Larger companies dominate cancer companion diagnostic approvals.
authors: Charles
authors: C
authors: Schmidt
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy; D000077547:Crizotinib; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics*; D006801:Humans; D007211:Indoles / Q000191:economics; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000191:economics / Q000627:therapeutic use; D011720:Pyrazoles / Q000191:economics / Q000627:therapeutic use; D011725:Pyridines / Q000191:economics / Q000627:therapeutic use; D011933:Reagent Kits, Diagnostic / Q000191:economics*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000191:economics; D013449:Sulfonamides / Q000191:economics; D014481:United States; D014486:United States Food and Drug Administration / Q000191:economics*; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D011933:Reagent Kits, Diagnostic; D013449:Sulfonamides; D000077484:Vemurafenib; D000077547:Crizotinib; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases